- Home
- CERO vs ENVB Comparison
CERO vs ENVB Comparison
Compare CERO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- ENVB
- Stock Information
- Founded
- CERO 2017
- ENVB 1994
- Country
- CERO United States
- ENVB United States
- Employees
- CERO 8
- ENVB N/A
- Industry
- CERO
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- ENVB Health Care
- Exchange
- CERO Nasdaq
- ENVB Nasdaq
- Market Cap
- CERO 3.7M
- ENVB 3.2M
- IPO Year
- CERO N/A
- ENVB N/A
- Fundamental
- Price
- CERO $0.45
- ENVB $1.30
- Analyst Decision
- CERO Buy
- ENVB Strong Buy
- Analyst Count
- CERO 2
- ENVB 1
- Target Price
- CERO $3.00
- ENVB $10.00
- AVG Volume (30 Days)
- CERO 993.4K
- ENVB 461.6K
- Earning Date
- CERO 05-15-2025
- ENVB 05-14-2025
- Dividend Yield
- CERO N/A
- ENVB N/A
- EPS Growth
- CERO N/A
- ENVB N/A
- EPS
- CERO N/A
- ENVB N/A
- Revenue
- CERO N/A
- ENVB N/A
- Revenue This Year
- CERO N/A
- ENVB N/A
- Revenue Next Year
- CERO N/A
- ENVB N/A
- P/E Ratio
- CERO N/A
- ENVB N/A
- Revenue Growth
- CERO N/A
- ENVB N/A
- 52 Week Low
- CERO $0.40
- ENVB $1.01
- 52 Week High
- CERO $102.00
- ENVB $11.82
- Technical
- Relative Strength Index (RSI)
- CERO 35.19
- ENVB 45.17
- Support Level
- CERO $0.42
- ENVB $1.11
- Resistance Level
- CERO $0.50
- ENVB $1.34
- Average True Range (ATR)
- CERO 0.05
- ENVB 0.10
- MACD
- CERO 0.00
- ENVB 0.04
- Stochastic Oscillator
- CERO 24.77
- ENVB 70.26
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.